What is Fabry disease

Fabry disease is a rare, progressive genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A, which leads to the harmful accumulation of a fatty substance called globotriaosylceramide (Gb3) in the body's cells. This multisystem condition affects the heart, kidneys, nervous system, and skin, requiring lifelong management by a specialized medical team.

What causes Fabry disease and how does it affect the body?

Fabry disease occurs due to mutations in the GLA gene, which is responsible for producing the alpha-galactosidase A enzyme. Without enough of this enzyme, Gb3 accumulates in the lysosomes of cells throughout the body. Over time, this buildup damages blood vessel walls and impairs the function of vital organs. Because it is a systemic disorder, Fabry disease can affect many body systems, most notably leading to kidney failure, heart disease (such as hypertrophic cardiomyopathy or arrhythmias), and nerve-related pain, known as acroparesthesia.

Is Fabry disease hereditary and who is affected?

Fabry disease is inherited in an X-linked pattern, meaning the faulty gene is located on the X chromosome. Because males have only one X chromosome, they typically experience more severe symptoms and an earlier onset of the disease. Females have two X chromosomes and may experience a wide spectrum of severity, ranging from asymptomatic to symptoms as severe as those seen in males. While prevalence estimates vary, Fabry disease is generally estimated to affect between 1 in 40,000 to 1 in 117,000 individuals, though newborn screening studies suggest the condition may be more common than previously thought.

What are the primary clinical classifications of Fabry disease?

Clinicians typically categorize Fabry disease into two main phenotypes based on the severity of the enzyme deficiency:

• Classic Fabry disease: Characterized by very low or absent enzyme activity. Symptoms often begin in childhood or adolescence, including burning pain in the hands and feet, decreased sweating (hypohidrosis), and characteristic skin lesions called angiokeratomas.


• Late-onset (Non-classic) Fabry disease: Characterized by residual enzyme activity. Symptoms typically manifest in adulthood and predominantly affect the heart (cardiac variant) or kidneys (renal variant), often without the childhood pain symptoms associated with the classic form.

How does Fabry disease differ from other conditions?

Unlike many other storage disorders, Fabry disease is unique in its specific pattern of systemic vascular damage. While other conditions might focus on a single organ, the widespread nature of Gb3 accumulation means that a patient may present with a complex combination of stroke, cardiac arrhythmias, and renal insufficiency. The presence of angiokeratomas—small, reddish-purple skin spots usually found on the torso or groin—is a clinical hallmark that helps doctors distinguish Fabry disease from other inherited cardiomyopathies or neuropathies.

Next steps

• Consult a metabolic specialist or a geneticist to discuss diagnostic testing, such as enzyme activity assays or genetic sequencing.


• Join the DiseaseMaps.org community to connect with the 174 members who are currently sharing their personal experiences living with this diagnosis.


• Request a referral to a multidisciplinary center of excellence that provides access to enzyme replacement therapy (ERT) or chaperone therapy.


• Encourage family members to undergo genetic counseling and testing, as Fabry disease is a hereditary condition.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Fabry disease overview.


• Orphanet: Rare disease database entry for Fabry disease (ORPHA:324).


• OMIM (Online Mendelian Inheritance in Man): Entry #301500 for Alpha-galactosidase A deficiency.


• National Fabry Disease Foundation: Patient resources and clinical guidelines.